title: Retrospective analysis of 119 small bowel adenocarcinoma in Chinese patients.
abstract: BACKGROUND
  Small bowel adenocarcinoma (SBA) is a rare occurrence and few studies have addressed it adequately, especially in China.
  
  
  METHODS
  Clinicopathological features, survival and prognostic analysis were retrospectively done in SBA patients admitted between 2001 and 2011 in the People's Liberation Army General Hospital.
  
  
  RESULTS
  The study included 68 men and 51 women with a median age of 56.5 year. Tumors mainly occurred in duodenum (93.3%). Abdominal pain was the most frequent symptom (36.8%). Patients (30.3%) who received postoperative adjuvant chemotherapy had an increased, but not significant, median overall survival (MOS) rate compared to those who did not receive chemotherapy (37 vs 35 months, p = .324). One year disease free survival rate was higher in patients receiving postoperative chemotherapy (83.3% vs 71.1%). Patients survived longer in the curative surgery group (median survival time of 49.0 months) than those in the palliative group (7.0 months) (p < .001). Node-negative patients survived longer than node-positive patients (median OS: 49.0 vs 21.0 months, p = .004). Depth (95% CI: 1.013-1.517, p = .037), node involvement (95% CI: 1.234-3.890, p = .007), palliative surgery (95% CI, 2.998-10.555, p = .0005), and the site of tumor (95% CI: 0.052-0.970, p = .045) were independent predictors of OS in a multivariate analysis.
  
  
  CONCLUSIONS
  SBA is rare and there is lack of obvious clinical manifestations. Depth, node involvement, palliative surgery, and the site of tumor are associated with a poor prognosis. Our analysis highlights the need for further studies to find out the exact role of postoperative adjuvant chemotherapy in these patients.
authors.affiliation: Department of Oncology, Chinese PLA General Hospital , Beijing , China.
authors.forename: Xiao-Chuan
authors.initials: XC
authors.lastname: Guo
authors.forename: Zhi-Yuan
authors.initials: ZY
authors.lastname: Mao
authors.forename: Dan
authors.initials: D
authors.lastname: Su
authors.forename: Li-Jie
authors.initials: LJ
authors.lastname: Wang
authors.forename: Ting-Ting
authors.initials: TT
authors.lastname: Zhang
authors.forename: Li
authors.initials: L
authors.lastname: Bai
mesh_terms: D015746:Abdominal Pain / Q000453:epidemiology; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality / Q000601:surgery*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D018395:CA-19-9 Antigen / Q000378:metabolism; D000069287:Capecitabine; D002272:Carcinoembryonic Antigen / Q000378:metabolism; D017024:Chemotherapy, Adjuvant; D002681:China / Q000453:epidemiology; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D018572:Disease-Free Survival; D004379:Duodenal Neoplasms / Q000188:drug therapy* / Q000453:epidemiology / Q000401:mortality / Q000601:surgery*; D004386:Duodenum / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D002955:Leucovorin / Q000627:therapeutic use; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010071:Oxaloacetates; D010166:Palliative Care; D012189:Retrospective Studies; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D018395:CA-19-9 Antigen; D002272:Carcinoembryonic Antigen; D009944:Organoplatinum Compounds; D010071:Oxaloacetates; D003841:Deoxycytidine; D000069287:Capecitabine; D002955:Leucovorin; D005472:Fluorouracil